Karam Diaby

Updated Cost-Effectiveness Analysis of Brexpiprazole for Adjunctive Treatment in Major Depressive Disorder in the United States

Abstract: Background: A 2017 published cost-effectiveness analysis of brexpiprazole compared to quetiapine-150 mg/day, quetiapine-300 mg/day, olanzapine/fluoxetine 50mg-12mg/day and antid...

Karam Diaby ;

01/19/2023

Budget Impact of Aripiprazole 2-Month Ready to Use Long-Acting Injectable for Adult Patients with Schizophrenia in the United States

Abstract: Background Aripiprazole 2-Month Ready to Use (ARI 2M RTU) formulation is a long-acting injectable (LAI) currently in development as a treatment for schizophrenia and maintenance...

Karam Diaby ;

01/19/2023

Budget Impact of Aripiprazole 2-Month Ready to Use Long-Acting Injectable for Adult Patients with Bipolar I Disorder in the United States

Abstract: Background Aripiprazole 2-Month Ready to Use (ARI 2M RTU) formulation is a long-acting injectable (LAI) currently in development as a treatment for schizophrenia and maintenance...

Karam Diaby ;

01/19/2023